Nurix Therapeutics discovers drugs that harness the body's natural process to control protein levels.
Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases.
Our focus is on developing drugs to treat cancer including novel, small molecule immuno-oncology agents.
Total raised: $145.1M
Founded date: 2012
Investors 1
| Date | Name | Website |
| - | The Column... | thecolumng... |
Funding Rounds 2
| Date | Series | Amount | Investors | Deal News |
| 12.03.2020 | - | $120M | - | biospace.c... |
| 22.05.2014 | Series B | $25.1M | - | vcnewsdail... |
Mentions in press and media 5
| Date | Title | Description | Category | Author | Source |
| 13.03.2020 | After Kyme... | Sanofi- and Gilead Sciences-ba... | Biotech | - | fiercebiot... |
| 22.05.2014 | Nurix Land... | SAN FRANCISCO, CA, Nurix has... | - | - | vcnewsdail... |
| 22.05.2014 | Nurix Rais... | Nurix, Inc., a San Francisco, ... | funding S... | - | finsmes.co... |
| 04.04.2013 | Stealthy b... | Formed in 2009 as Kura Therape... | - | - | medcitynew... |
| - | Stealthy b... | Another early stage California... | - | - | medcitynew... |